Rate My Professor David Owen

Owen's research specializations include protein science, nanotechnology, radiotheranostics, cancer biology, and bioconjugation. He has produced 48 published works, accumulating 1,647 citations and an h-index of 23 according to Scopus/SciVal data from 2023. Key publications feature 'Nanobody-mediated cellular uptake maximizes the potency of polylysine dendrimers while preserving solid tumor penetration' in ACS Nano (2025), 'In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate' in the International Journal of Pharmaceutics (2023), 'Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma' in the Journal of Controlled Release (2022), and 'Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy' in Communications Biology (2021). Earlier contributions encompass studies on pulmonary administration of dendrimer formulations and lymphatic targeting of anticancer agents. As an inventor, he holds 4 granted patents and 18 patent applications, notably on dendrimer-drug conjugates and macromolecules, underscoring his substantial impact on nanomedicine and biopharmaceutical development.